Enhancing the specificity of microglia genetic targeting using a CSF1R inhibitor Authors: Isaac W Babcock, Sydney A Labuzan, Abigail G Kelly, Anne E Schuster, Seblework Alemu, Lydia A Sibley, Anne E Marchildon, Tajie H Harris Published: 2026 ABSTRACT SUMMARYMicroglia are the resident macrophages of the brain and are central to neuroimmunology research. The roles of microglia are often probed by pharmacological depletion with CSF1R inhibitors or by genetic manipulation using Cre-lox systems, but microglia-specific genetic targeting remains challenging due to limited specificity or efficiency of Cre lines. We confirm that Cx3cr1CreERT2 mice, widely used for microglial studies, also target multiple peripheral tissue macrophage populations that fail to turn over within the standard 4-week period intended to improve specificity. To overcome this limitation, we combined tamoxifen induction in Cx3cr1CreERT2 mice with PLX5622 treatment to accelerate peripheral macrophage turnover. In a brain infection model, this strategy increased the specificity of gene deletion in microglia in Cx3cr1CreERT2 mice and eliminated confounding contributions from peripheral macrophages. In sum, the use of a CSF1R inhibitor provides a solution to enhance the precision of microglial genetic manipulation using a common Cre line. INTRODUCTION Macrophages are sentinel immune cells present in all tissues that coordinate the initiation and resolution of inflammation. In the central nervous system (CNS), microglia are the resident macrophage population that plays critical roles in neurodevelopment, immune surveillance, and neurodegeneration. Derived from yolk sac progenitors, microglia self-renew and persist throughout life.1 To study microglia in vivo, CSF1R inhibition using small molecules (e.g., PLX5622) is a widely used method for depleting microglia. Prior experiments using PLX5622 have demonstrated that microglia repopulate from residual microglia. However, the extent to which peripheral macrophages are depleted with PLX5622 and the sources from which they repopulate continue to be an area of investigation.2-6 While initially proposed that peripheral macrophages are continuously replenished by bone marrow-derived monocytes, subsequent studies have identified self-maintaining macrophage populations in peripheral tissues under homeostasis.2,7-9 However, inflammation can trigger the replacement of embryonically derived macrophages by monocytes, raising questions regarding the extent to which macrophage ontogeny confers distinct functional properties.2,8,10-12 Furthermore, increased knowledge of the longevity of tissue-resident macrophages prompts reinvestigation into Cre-driven microglial targeting strategies that assume that peripheral macrophages will be replaced by unlabeled/untargeted monocytes over time. To study microglia, Cre-lox systems are commonly employed, though current models necessitate trade-offs between specificity and recombination efficiency. The Cx3cr1CreERT2 lines achieve near-complete recombination in microglia but also target peripheral monocytes and macrophages.13-15 By contrast, microglia-specific Cre promoters such as Hexb, Tmem119, and P2ry12 offer improved specificity but exhibit markedly lower recombination efficiency.16,17 While Cx3cr1CreERT2 is often favored for the ability to target nearly all microglia, the reliance on peripheral myeloid cell turnover to limit recombination outside the CNS raises concerns. The long-term persistence of Cx3cr1-expressing peripheral macrophages targeted by Cx3cr1CreERT2 has not been fully characterized and may complicate experimental interpretations in contexts where both microglia and peripheral macrophages contribute to immune responses. This distinction is particularly important in CNS infections such as Toxoplasma gondii, where both microglia and peripheral Cx3cr1+ macrophages participate in immune reactions that lead to parasite control.18,19 T. gondii infection begins with an acute peripheral phase before establishing a lifelong chronic infection in the brain. Persistent immune pressure within the CNS is essential for host survival, making T. gondii an informative model for investigating how immune responses are generated and maintained in the brain. During chronic infection, CNS-resident macrophages facilitate monocyte infiltration into the CNS via gasdermin D-dependent release of IL-1α.18 Caspase-1 is a central regulator of gasdermin D-dependent pore formation; however, it remains unclear whether caspase-1 is necessary for monocyte recruitment during CNS infection. In the periphery, Cx3cr1+ cells contribute to adaptive immunity and parasite control through caspase-1-mediated IL-18 release.19 However, it remains unclear whether microglia or CNS border-associated macrophages (BAMs) also employ caspase-1 to promote monocyte recruitment during CNS infection. Here, we show that targeting microglia using the Cx3cr1CreERT2 approach is confounded by populations of long-lived peripheral Cx3cr1-expressing macrophages. We find that numerous tissues retain Cre-targeted macrophages that persist for months post-tamoxifen treatment. Importantly, the degree of macrophage Cre targeting differs by tissue. To speed up the turnover of peripheral macrophage populations and to enhance the specificity of the Cx3cr1CreERT2 system for microglia, we treated mice with the CSF1R antagonist PLX5622. We found that PLX5622 targets numerous peripheral macrophage compartments, depleting cells that are targeted by Cx3cr1CreERT2. Following PLX5622 withdrawal, macrophage populations throughout the body were replenished. Microglial populations retained genetic manipulations induced by Cre, and peripheral populations were partially re-seeded from untargeted progenitor cells. The use of PLX5622 in combination with Cx3cr1CreERT2 allowed us to address that the ontogeny of peripheral macrophages (particularly in the peritoneal cavity) did not influence acute and chronic immune responses to infection. Importantly, we were also able to increase the specificity of recombination to microglia, which revealed that Casp1 in microglia is dispensable for parasite control. Overall, this study provides insights into the specificity of two commonly used approaches to study microglia and provides a generalizable strategy to enhance the specificity of the Cx3cr1CreERT2-lox system to manipulate microglia. RESULTS Long-lived Cx3cr1-expressing cells utilize caspase-1 to promote T. gondii control during chronic and acute infection Based on previous studies, we wanted to address the role of microglial caspase-1 during CNS infection.18,20 Prior studies demonstrated that microglia are critical responders to CNS infection and form inflammasomes.18,20 However, it remained unclear whether microglia activate caspase-1 to promote neuroinflammation during CNS infection. This question is particularly relevant given that mice globally deficient in caspase-1 or in caspase-1/11 exhibit impaired CNS pathogen control.18,19 First, we assessed immune responses in whole-body caspase-1-deficient mice. We infected wild-type (WT) and Casp1 knockout (KO) mice via intraperitoneal (i.p.) injection with 10 cysts of the type II T. gondii Me49 strain. At 6 weeks post-infection (wpi), representing a chronic time point, immune cells were isolated from the brain and assessed by flow cytometry. While T cell responses were intact, we observed a selective defect in monocyte recruitment in Casp1 KO mice compared to WT controls (Figure 1A). This defect was driven by a reduced percentage of monocytes infiltrating the infected CNS of Casp1 KO mice (Figure 1B). Initially, to ask whether microglia are the critical cell population utilizing caspase-1, we generated Cx3cr1CreERT2 × Casp1FL/FL or Casp1WT/WT mice. We administered 5 doses of tamoxifen (20 mg/kg) to Cx3cr1CreERT2 × Casp1FL/FL and Cx3cr1CreERT2 × Casp1WT/WT mice and waited the standard 4 weeks to allow short-lived recombined myeloid cells to turn over prior to infection (Figure 1C). We observed impaired parasite control and a selective impairment in monocyte recruitment into the CNS of infected Cx3cr1CreERT2 × Casp1FL/FL mice at 6 wpi (Figures 1D-1F). These data suggest that a long-lasting Cx3cr1-expressing population, like microglia, utilizes caspase-1 to promote monocyte infiltration into the CNS to control T. gondii. However, we had previously established that caspase-1 in a Cx3cr1-expressing population promotes T. gondii control during the acute stage of infection.19 Thus, we aimed to determine whether any defects occur during the acute phase of infection in the Cx3cr1CreERT2 × Casp1FL/FL mice. To this end, Cx3cr1CreERT2 × Casp1FL/FL or Cx3cr1CreERT2 × Casp1WT/WT controls were administered 5 doses of tamoxifen, allowed 4 weeks for short-lived recombined myeloid cells to turn over, and then infected with 10 cysts of Me49. Peritoneal exudate cells and splenocytes were harvested at 8 days post-infection (dpi). Notably, we observed impaired parasite control in the peritoneal cavity and a significant decrease in CD4+ T cell IFN-γ production (Figures 1G and 1H). These findings phenocopy what we observed previously in Cx3cr1 constitutive Cre × Casp1FL/FL mice, suggesting that caspase-1 in a long-lived peripheral macrophage population, the precise anatomical location unresolved, contributes to acute parasite control.19 Additionally, these data raise the possibility that the increased parasite burden observed at the chronic stage of infection in Cx3cr1CreERT2 × Casp1FL/FL mice (Figure 1D) may have resulted from impaired parasite control during the acute phase of infection (Figure 1G). This observation also prompted reconsideration of whether all peripheral macrophage populations undergo turnover within the standard 4-week interval allotted following tamoxifen treatment. Long-lived Cx3cr1-expressing cells utilize caspase-1 to promote T. gondii control during chronic and acute infection (A and B) Two experimental replicates were performed in female mice. (A) Number of immune cells in brains of WT and Casp1-deficient mice infected with T. gondii for 6 weeks. Immune cells analyzed via flow cytometry of single-cell suspensions isolated from the brain. (B) Frequency of monocytes as a percentage of live cells in infected WT and Casp1-deficient T. gondii-infected brains. (C) Experimental timeline to test the role of tissue-resident macrophage caspase-1 during T. gondii infection. (D–F) Two experimental replicates were performed utilizing male and female mice. (D) Quantitative PCR of parasite genomes in brains of Cx3cr1CreERT2 × Casp1FL/FL (FL/FL) or Cx3cr1CreERT2 × Casp1WT/WT (WT/WT) mice infected with T. gondii for 6 weeks. (E) Number of immune cells in brains of FL/FL or WT/WT mice infected with T. gondii for 6 weeks. Immune cells analyzed via flow cytometry of single-cell suspensions isolated from the brain. (F) Frequency of monocytes as a percentage of live cells in T. gondii-infected FL/FL or WT/WT brains. (G and H) Two experimental replicates were performed in female mice. (G) Quantitative PCR of parasite genomes in peritoneal exudate cells from FL/FL or WT/WT mice infected with T. gondii for 8 days. (H) Number of IFN-γ-producing CD4+ T cells in the spleens of FL/FL or WT/WT mice infected with T. gondii for 8 days. (A, B, and D–H) All data points and p values represented in figure, p value generated from randomized block ANOVA with post hoc Tukey’s test. Error bars are SEM. Cx3cr1CreERT2 targets long-lived peripheral macrophages Studies have shown that Cx3cr1CreERT2 targets peripheral macrophages and monocytes. Multiple reports have examined this recombination in tissue-resident macrophage populations—including CNS BAMs, skin, liver, lungs, and blood—and some of these studies have tracked the persistence of labeled cells over time to assess their turnover and longevity.14,15,21-23 However, these studies often focused on tissue-specific contexts, without directly addressing the temporal dynamics in relation to microglial targeting strategies. To build on this work, we conducted a tracing experiment using Cx3cr1CreERT2 × ROSA26 Ai6/Ai6 mice to assess the turnover of Cx3cr1-expressing macrophages (Figure 2A). Mice were administered five doses of tamoxifen at 20 mg/kg; examined at 4 days, 4 weeks, and 4 months post-tamoxifen; and analyzed for the percentage of macrophages reporting Cre activity by ZsGreen expression.13,21 We analyzed microglia, meninges, skin, lungs, peritoneum, spleen, deep cervical lymph node (DCLN), liver, and blood macrophages. Representative gating strategies for macrophages within these tissues are shown in Figures S1A-S1H. We then characterized the different macrophage populations into three categories: “slow turnover” equating to less than 50% turnover in 4 months, “intermediate turnover” being less than 50% turnover in 4 weeks but achieving 50% turnover in 4 months, or “rapid turnover” having more than 50% turnover in 4 weeks. As expected, minimal labeling was observed in liver macrophages (Figures S2B and S2C), and blood Ly6C-high monocytes rapidly lost ZsGreen expression while Ly6C-low monocytes had a slower decay (Figures S2D and S2E). Furthermore, in sham-injected mice, we observed minimal ZsGreen+ events in peritoneal, splenic, DCLN, skin, and MHCII-positive lung macrophages but did detect appreciable labeling in microglia, meningeal, and MHCII-negative lung macrophages (Figures S2F and S2G). Despite this baseline recombination, tamoxifen treatment consistently increased ZsGreen labeling in these populations, indicating robust inducibility above the baseline level. These data support that Cx3cr1CreERT2 × ROSA26 Ai6/Ai6 mice report Cx3cr1CreERT2-mediated recombination with detectable tamoxifen-independent activity in select tissue-resident populations. Using tamoxifen-induced labeling, we next assessed macrophage recombination over time. Consistent with prior reports, microglia and meningeal macrophages persisted (Figure 2B).15 Notably, we also observed that splenic and MHCII-negative skin macrophages were also long lived (Figure 2B). However, the maximal percentage of splenic and MHCII-negative skin macrophages labeled was fewer than microglia or meningeal macrophages (Figure 2B). These observations align with previous studies reporting that splenic macrophages are slow to turn over and that MHCII-negative skin macrophages labeled by Cx3cr1CreERT2 are long lasting.21,22 Intermediate-lasting macrophages included MHCII-positive and MHCII-negative lung macrophages, MHCII-positive skin macrophages, and DCLN macrophages (Figures 2C, S2G, and S2H). Peritoneal macrophages showed reduced ZsGreen expression in the 4-week window and were grouped within the rapidly turning over population that included Ly6C-high and -low blood monocytes (Figure 2D). These findings are largely consistent with previous reports,13-15,21-23 except peritoneal macrophages; prior studies utilizing similar gating strategies but different routes of tamoxifen administration (oral gavage or subcutaneous delivery) did not observe robust labeling of peritoneal macrophages.13,21 In line with our findings, lineage tracing studies observed a slower rate of monocyte replacement of peritoneal macrophages.21 Interestingly, we observed that repeat tamoxifen injection into the peritoneal cavity resulted in the disappearance of F4/80hi macrophages, which reappeared at later time points (Figure S1Ea and S1Eb). This observation suggests that the initial high percentage of labeling in the peritoneum 4 days after tamoxifen withdrawal is due to the temporary loss of the sizable F4/80hi macrophage compartment. Inducible Cx3cr1CreERT2 targets long-lived peripheral macrophages (A) Schematic outlining experiment to track Cx3cr1CreERT2-targeted macrophages. (B–D) Percentage of ZsGreen-expressing (Cre-driven recombination) macrophage populations in multiple tissues separated into either slow-turnover macrophage populations having <50% turnover in 4 months (B), intermediate-turnover macrophages having <50% turnover in 4 weeks but >50% turnover in 4 months (C), or rapid-turnover monocyte and macrophages having >50% turnover in 4 weeks (D). All time points were performed in duplicate; the 4-day and 4-week replicates were from male mice, while the 4-month time point included one replicate from male mice and the other from female mice. All mice were treated with tamoxifen at 4–6 weeks of age. Each data point represents the mean percentage of ZsGreen-positive macrophages from 6 to 8 mice. Error bars are SEM. Together, these data highlight that at 4 weeks post-tamoxifen treatment, little turnover of peripheral Cx3cr1CreERT2-targeted resident macrophages occurred, and by 4 months, MHCII-negative skin macrophages, splenic macrophages, meningeal macrophages, and microglia had minimal turnover from unlabeled progenitors. These results align with previous Cx3cr1CreERT2 tracing experiments; however, compared to previous tracing experiments, the magnitude of labeling in this study was greater due to highly efficient recombination in the Ai6 Cre-reporter mice or the high dose of tamoxifen, which is not required to elicit recombination in Ai6 mice but rather is often required for targeting floxed genes of interest.20,22,24 Notably, the slow turnover of specific macrophage populations corresponds with recent monocyte tracing studies showing that monocyte engraftment into macrophage niches is slow and levels off when the mice are 12 weeks of age.21 Collectively, these findings align with previous studies on peripheral macrophages and demonstrate that Cx3cr1CreERT2 induces recombination in multiple long-lived peripheral macrophage populations, highlighting the importance of accounting for Cre activity beyond microglia and exploring strategies to improve targeting specificity. CSF1R antagonism depletes Cx3cr1CreERT2-targeted macrophages Early studies identified CSF1R signaling as a critical macrophage survival cue.25 Pharmacological inhibition of CSF1R with PLX3397 or PLX5622 has become a common strategy to deplete microglia, revealing that following short-term depletion, microglia repopulate from surviving microglia with minimal monocyte contribution.26-28 Although multiple studies have demonstrated the impact of PLX5622 on peripheral immune populations, PLX5622 is still widely used to deplete microglia.5,6,25,28-32 We hypothesized that administering PLX5622 after tamoxifen treatment of Cx3cr1CreERT2 mice would deplete peripheral macrophages that had undergone Cre-driven recombination, and following drug withdrawal, these cells would be repopulated by ZsGreen-negative progenitors, likely from the bone marrow. Because microglial repopulation is monocyte independent, microglia would repopulate from the remaining recombined microglia, thereby enhancing Cx3cr1CreERT2 specificity for microglia. To characterize PLX5622 depletion of Cx3cr1CreERT2-targeted long-lasting peripheral macrophages, we utilized Cx3cr1CreERT2 × ROSA26Ai6/Ai6 mice. After inducing recombination with five tamoxifen injections intraperitoneally, we allowed the mice to recover for 7–10 days. Then, mice were fed either PLX5622 mouse chow at 1,200 parts per million or control chow for 10 days before analysis (Figure 3A). We observed, as expected, that PLX5622 efficiently depleted recombined microglia (Figures 3B and 3C). Furthermore, we identified that the CSF1R antagonist PLX5622 significantly depleted all recombined macrophage populations analyzed. ZsGreen-positive meningeal and lung macrophages showed robust depletion, while other populations, such as those in the spleen and small intestine mucosa, exhibited significant but less pronounced reductions (Figures 3D-3O). Notably, PLX5622 broadly depleted both ZsGreen-positive and total macrophage populations across tissues, with the exception of the lung (Figures S3A-S3M). In the lung, only a subset of parenchymal macrophages identified by Cx3cr1 expression are CSF1R antagonist sensitive, whereas alveolar macrophages (Cx3cr1 negative) are not dependent on CSF1R signaling for survival.23,33 Overall, these findings are consistent with prior studies using genetic KO/rescue experiments, CSF1R-blocking antibodies, or PLX5622 to investigate the survival requirements of distinct macrophage populations.5,6,23,32 Together, these data show that PLX5622 not only efficiently depletes microglia but also depletes Cx3cr1CreERT2-targeted macrophages throughout the body. CSF1R antagonism depletes Cx3cr1CreERT2-targeted macrophages (A) Timeline for depleting Cx3cr1CreERT2-targeted macrophages using PLX5622 (1,200 ppm)-formulated mouse chow in AIN-76A rodent diet. (B) Representative flow cytometry plots from control (AIN-76A) and PLX5622 chow-treated mice after 10 days of treatment. Flow cytometry was performed on single-cell suspensions from brain and pre-gated on size, singlets, live, Ly6c−, CD3−, ZsGreen+ to identify microglia (CD11b int CD45 int). (C) ZsGreen+ microglia were quantified after PLX5622 treatment. (D) Representative flow cytometry plots of single-cell suspensions isolated from dural meninges from PLX5622 and control-treated mice. (E–L) Quantification of the number of ZsGreen+ MHCII+ meningeal macrophages (E), MHCII− meningeal macrophages (F), splenic macrophages (G), peritoneal macrophages (H), MHCII+ lung macrophages (I), MHCII− lung macrophages (J), MHCII+ skin macrophages (K), and MHCII− skin macrophages (L) after PLX5622 treatment. (M) Confocal images of small intestine visualizing ZsGreen+ cells (green) and DAPI (blue) after PLX5622 treatment. Scale bars, 50 μm. (N) Quantification of small intestine ZsGreen+ area within DAPI area. (O) Summary plot representing the mean percentage of ZsGreen+ macrophages depleted by PLX5622 treatment. Error bars are SEM. (AvgControl−AvgPLXAvgControl)∗100. All experiments were performed using male mice. (C and E–L) Two experimental replicates, all data points represented in graphs. Data were analyzed using a randomized block ANOVA with post hoc Tukey’s test. Error bars are SEM. (N) Single experiment, n = 3 mice, each data point is the average of 2–17 ROIs per intestine. Statistical analysis was performed using the Welch’s unpaired t test with Welch’s correction. Error bars are SEM. CSF1R antagonist-based macrophage depletion and repopulation result in significantly fewer peripheral macrophages that have undergone Cx3cr1CreERT2-driven recombination Observing that CSF1R antagonist treatment depleted Cx3cr1CreERT2-recombined macrophage populations to varying extents, we asked if repopulation of the macrophage niches would replace ZsGreen-positive peripheral macrophages with ZsGreen-negative macrophages while leaving microglial recombination intact. To address this question, we utilized Cx3cr1CreERT2 × ROSA26 Ai6/Ai6 mice, induced recombination with tamoxifen, and then allowed 1 week of recovery before placing half the mice on PLX5622 and the other half on a control diet for 10 days. After the 10-day depletion, we withdrew PLX5622 and returned all mice to standard chow for 14 days to allow macrophage niches to repopulate (Figure 4A). Importantly, we observed no change in the percentage of microglia that are ZsGreen+ after repopulation (Figures 4B and 4C). These data are in line with previous work demonstrating that microglia self-renew from a local microglial source.8,34 Next, we analyzed both a slow-turnover (dural meningeal macs) and a rapid-turnover (peritoneal macs) population to determine if the macrophage depletion/repopulation strategy is effective at reducing ZsGreen-positive macrophages from these sources. In the dural meninges, we observed a significant reduction in the percentage of ZsGreen-positive macrophages post-repopulation (Figures 4D and 4E). We further confirmed this finding through microscopy of whole-mount dural meninges (Figures 4F and 4G). In the repopulation group, we observed many ZsGreen-negative Iba1+ cells in both regions near (Figures 4Fa and 4Ga) and distant (Figures 4Fb and 4Gb) to large blood vessels. These data are in alignment with previous studies that have demonstrated that the depletion of meningeal macrophages using various methods results in the partial replacement of BAMs with monocyte-derived macrophages.35-37 In the peritoneum, 4 weeks post-recombination, ~17% of peritoneal macrophages are ZsGreen positive (Figures 2D, 4H, and 4I), and depletion/repopulation was able to further reduce the percentage of ZsGreen-positive peritoneal macrophages to ~6% (Figures 4H and 4I). Furthermore, when we analyzed additional ZsGreen-positive macrophage populations throughout the periphery, we observed significant replacement of all Cx3cr1CreERT2-recombined macrophage populations and also reduced variation in the degree of macrophage combination between mice (Figures S4A-S4K). However, the percentage of ZsGreen-positive macrophages replaced varied greatly depending on the tissue (Figure 4J). Collectively, these data demonstrate that utilizing Cx3cr1CreERT2 in conjunction with transient CSF1R antagonism markedly improves the specificity of Cx3cr1CreERT2 for microglia compared to the conventional 4-week post-tamoxifen interval and provides a strategy to disentangle the functions of microglia versus long-lived peripheral macrophages.14,15 CSF1R antagonist-based macrophage depletion and repopulation result in significantly fewer peripheral macrophages with Cx3cr1CreERT2-driven recombination (A) Approach for replacing Cx3cr1CreERT2-targeted macrophages. PLX5622 (1,200 ppm) formulated in AIN-76A rodent diet (Repop group) or control (AIN-76A) rodent diet (Control group) was administered for 10 days followed by 14 days of recovery. (B) Representative flow cytometry plots showing microglia ZsGreen expression from Repop and Control-treated mice. (C) Percentage of ZsGreen+ microglia after repopulation. (D) Representative flow cytometry plots of macrophages from dural meninges expressing ZsGreen in Repop and Control-treated mice. (E) Percentage of ZsGreen+ meningeal macrophages after repopulation. (F and G) Representative immunohistochemistry tile scan of whole-mount dural meninges from Repop and Control-treated mice visualizing IBA1 (magenta), ZsGreen (green), and DAPI (blue). Scale bars, 100 μm. Insets highlighting vessel-associated macrophages (Fa and Ga) and tissue macrophages (Fb and Gb). Scale bars, 20 μm. (H) Representative flow cytometry plots of peritoneal macrophage ZsGreen expression from sham (tamoxifen-negative control), Control, and Repop-treated mice. (I) Percentage of ZsGreen+ peritoneal macrophages after repopulation. (J) Summary plot representing percentage of ZsGreen-positive cells replaced by ZsGreen-negative cells after repopulation. (AvgControl−AvgRepopAvgControl)∗100. Data points are the mean replacement from two independent experimental replicates (spleen, peritoneum, lungs, skin, meninges, and microglia) or mean from single experiment (heart, small intestine, and leptomeninges) performed in male mice. Error bars are SEM. (C, E, and I) Two independent experimental replicates with all data points represented in graphs. Statistical analysis was performed using randomized block ANOVA with post hoc Tukey’s test. Error bars are SEM. Transient treatment with the CSF1R antagonist results in subtle changes to brain transcriptome and peripheral macrophages Observing that transient CSF1R antagonism provides a method to specify the Cx3cr1CreERT2 system, we wanted to evaluate whether this approach significantly impacts both the brain and peripheral macrophage populations. To perform an unbiased screen for changes in the CNS after CSF1R antagonist treatment, we utilized a bulk sequencing dataset published by Fu et al. to identify gene changes that occur between control-diet mice and CSF1R-antagonist depletion/repopulation mice (repop mice).38 In the Fu et al. study, they utilized WT C57BL/6 mice treated with either PLX3397 or control diet for 9 days and then withdrew the diet and returned to standard diet for 9 days prior to performing bulk RNA sequencing of the brain cortex (Figure 5A). Principal-component (PC) analysis revealed that control and repopulated mice separated along PC1 suggesting that repopulation does impact brain cortex transcription (Figure 5B). Differential gene analysis identified that 31 genes had a log2-fold change greater than 1 and only four genes had a log2-fold change greater than 2 (Figure 5C). These differentially regulated genes primarily fit into immune-related Gene Ontology (GO) terms (Figure S5A). In this study, we use PLX5622, which offers higher tissue penetrance and improved CSF1R specificity compared to PLX3397, for 10 days followed by 14 days of recovery; thus, we wanted to determine if similar transcriptional changes would occur (Figure 5D). First, we confirmed that upon repopulation, we had similar numbers of microglia compared to control mice (Figure 5E). Next, we performed quantitative PCR for immune and non-immune genes that were differentially expressed in the Fu et al. dataset. We observed no difference in interferon-regulated genes Ifit1, Ifit3, or Irf7, but in alignment with Fu et al., we observed a significant increase in Siglec1 and a significant decrease in Hba-a1, encoding for a monocyte/macrophage adhesion molecule and the hemoglobin alpha subunit, respectively (Figure 5F).39,40 Together, these data demonstrate that macrophage depletion and repopulation exert a negligible impact on transcriptional programs in the brain. Transient treatment with the CSF1R antagonist results in subtle changes to brain transcriptome and peripheral macrophages (A–C) Utilization of the GEO:GSE245107 dataset from Fu et al. to identify cortical gene changes after CSF1R-based repopulation. (A) Experimental timeline prior to bulk RNA sequencing of the brain cortex. (B) Principal-component analysis (PCA) plot of the first two principal components, which separate control-treated mice from PLX3397-repopulated mice. (C) Volcano plot of differentially expressed genes; genes highlighted in red were used for downstream analysis. (D) CSF1R depletion and drug withdrawal timeline used for (E)–(O). (E) Number of microglia in the brain post-repopulation. (F) Whole-brain RT-qPCR from Control and Repop mice using the genes identified in (C).(G–O) Number or percentage of macrophages in spleen (G), lungs (H and I), skin (J and K), peritoneum (L and M), and dural meninges (N and O), with the percentage of MHCII+ versus MHCII− macrophages shown in the second image for each tissue (I, K, M, and O). (G and H) Two independent experimental replicates (replicate #1 open shape, replicate #2 closed shape) are shown with separate means and SEMs due to variation in macrophage isolation efficiency between replicates. (E–O) Two independent experimental replicates with all data points represented in graphs were performed using male mice. Statistics were performed utilizing randomized block ANOVA with post hoc Tukey’s test. Error bars are SEM. Observing no difference in microglia numbers following a course of PLX treatment, we asked if this was the case for other macrophage populations. Additionally, as a correlate of macrophage ontogeny, we further interrogated if there were any shifts in the proportion of macrophages expressing MHCII.37,41 In the meninges, it has previously been shown that bone marrow-derived macrophages are often MHCII positive while embryonic-derived macrophages are MHCII negative. In contrast, in the lungs and skin, monocytes can differentiate into either MHCII-positive or -negative macrophages.15,24,42,43 In the spleen, macrophages could not be discerned as MHCII-positive or -negative populations, so an MHCII ratio was not calculated; however, repopulation did not alter splenic macrophage number (Figure 5G). Additionally, we observed no differences in the number of macrophages or in the distribution of their MHCII expression in either the lungs or skin (Figures 5H-5K). These findings are consistent with previous reports that lung macrophages can self-renew from local embryonic-derived niches, a process that would not necessarily alter MHCII expression.2,23,24 In the peritoneum, we did not observe a difference in the number of macrophages but did observe a significant decrease in MHCII-negative macrophages and a significant increase in MHCII-positive macrophages (Figures 5L and 5M). We observed the same phenotype in the dural meninges (Figures 5N and 5O). These data are in support of studies identifying peritoneal and meningeal macrophage niches being partially repopulated by monocyte-derived macrophages.10,12,37 We further interrogated peritoneal macrophages and their TNF-α production after repopulation and did not observe a significant difference (Figures S5B and S5C). Furthermore, given the impact of PLX5622 beyond macrophages, we analyzed T cell responses in the spleen and did not observe any difference in CD4+ and CD8+ T cell production of IL-17, TNF-α, or IFN-γ after repopulation (Figures S5D-S5G).5,6 These experiments reveal that transient treatment with the CSF1R antagonist results in subtle changes in gene transcription in the brain and significant shifts in MHCII-expressing macrophages in the meninges and peritoneum. It must be appreciated that sex, age, and sterility of the environment may influence distinct macrophage/monocyte dynamics during repopulation.8 Transient treatment with the CSF1R antagonist does not impact acute or chronic T. gondii infection The observed shifts in peritoneal and meningeal macrophage MHCII expression following PLX5622 depletion and repopulation are indicative of an increase in monocyte-derived macrophage contribution to these niches. Given the importance of macrophage responses during T. gondii infection,11,19,44,45 we asked whether transient CSF1R antagonism would impact host resistance to peripheral and CNS T. gondii infection. Mice were given a 10-day course of PLX5622 or control diet and then returned to standard chow for a 14-day repopulation period prior to i.p. infection with 10 cysts of Me49 (Figure 6A). Eight dpi, an acute infection time point where parasite responses are robust in the peritoneum, we observed no difference in parasite burden, systemic IFN-γ or IL-12 cytokine levels, neutrophil or monocyte recruitment to the site of infection, T cell activation in the spleen, or numbers of CD4+ and CD8+ T cells producing IFN-γ (Figures 6B-6I). At 6 wpi, a chronic phase of infection where the parasite and immune responses are largely restricted to the CNS, transient CSF1R antagonism did not impact host control of T. gondii (Figure 6J). Furthermore, we did not observe significant differences in monocyte or T cell recruitment to the CNS or in CD4+ and CD8+ T cell cytokine production (Figures 6K-6O). Together, these data demonstrate that macrophage depletion and repopulation do not alter host control or immune responses to T. gondii infection in the periphery or the CNS. Transient treatment with the CSF1R antagonist does not impact peripheral or chronic T. gondii infection (A–I) Performed using female mice. (A) Schematic of repopulation experiment with acute and chronic T. gondii infections. (B) Number of parasite genomes present in peritoneal exudate cells 8 days post-infection. (C and D) ELISA quantification of serum IFN-γ (C) and IL-12 (D) cytokine levels 8 days post-infection. (E and F) Number of peritoneal neutrophils (E) and monocyte (F) 8 days post-infection. (G) Number of activated CD4+ and CD8+ T cells in the spleen 8 days post-infection. (H and I) Number of CD4+ (H) and CD8+ (I) T cells producing IFN-γ in the peritoneum 8 days post-infection. (J) Number of parasite genomes present in brains at 6 weeks post-infection. (K) Representative flow plot of mononuclear cells isolated from the brain; gate indicates brain-infiltrating myeloid cells. (L) Number of monocytes in 6-week infected brains. (M) Number of T cells in 6-week infected brains. (N and O) Number of IFN-γ-producing T cells in 6-week infected brains. Statistical analysis was performed by randomized block ANOVA with post hoc Tukey’s test. Two independent experimental replicates using female mice (A–I) and male mice (J–O) with all data points represented in graphs. Error bars are SEM. Specifying Cx3cr1CreERT2 to microglia reveals that microglial caspase-1 is dispensable for T. gondii control Given that macrophage repopulation following CSF1R antagonist treatment had minimal impact on T. gondii control and enhanced the specificity of Cx3cr1CreERT2 for microglia, we leveraged this approach to revisit the original question of whether microglial caspase-1 contributes to control of CNS infection. First, we tested whether repopulation enhanced the specificity of Casp1 excision to microglia. We administered five doses of tamoxifen intraperitoneally to Cx3cr1CreERT2 × Casp1FL/FL or Cx3cr1CreERT2 × Casp1WT/WT control mice, allowed the mice to recover for 1 week, and then gave mice control or PLX5622 diet for 10 days followed by a 14-day recovery on standard chow (Repop or Control). We then harvested brain and dural meninges, magnetically enriched CD11b+ cells, and ran RT-qPCR for Casp1 (Figure 7A). As expected, the CNS Casp1 levels were depleted in both the FL/FL and FL/FL + Repop group, while in meningeal macrophages, only FL/FL mice had decreased levels of Casp1 compared to WT/WT controls (Figures 7B and 7C). We then utilized these mice and underwent the same recombination/repopulation paradigm, followed by infection with 10 cysts of the Me49 parasite, and analyzed them at either 8 dpi or 6 wpi (Figure 7D). Importantly, at 8 dpi, we observed significantly lower parasite levels in Casp1FL/FL mice on the repopulation diet compared to Casp1FL/FL mice on the control diet (Figure 7E). However, splenic CD4+ T cell IFN-γ production showed a modest, non-significant recovery (Figure 7F). These findings suggest that enhancing the specificity of Cx3cr1CreERT2 for microglia through transient CSF1R antagonism effectively restored acute peripheral parasite control in Cx3cr1CreERT2 × Casp1FL/FL mice. Given these data, we proceeded to a chronic, CNS-specific, time point where microglia are more likely to be involved in the immune response (6 wpi) to assess the role of microglial caspase-1. In contrast to the earlier findings (Figure 1D), where Cx3cr1CreERT2-targeted Casp1 in all long-lived macrophages resulted in impaired monocyte recruitment into the CNS and impaired control of T. gondii, restricting recombination to microglia revealed that Casp1 deletion in microglia had no impact on parasite control or immune responses in the infected CNS (Figures 7G-7I). These results suggest that caspase-1 in long-lived macrophages, other than microglia, promotes neuroinflammation and T. gondii control. Together, these data indicate that microglial caspase-1 is not required for immune responses or parasite control in the CNS during T. gondii infection. Combined with the findings in Figures 1D-1F, these data further suggest that a Cx3cr1-expressing population—susceptible to replacement under transient CSF1R inhibition—utilizes caspase-1 to drive neuroinflammation and promote parasite control. Microglial caspase-1 is dispensable for T. gondii control (A) Schematic for specifying Cx3cr1CreERT2 × Casp1FL/FL genetic manipulation to microglia. (B and C) RT-qPCR for Casp1 in CD11b-enriched cells from CNS (B) and dural meninges (C). Two experimental replicates, statistics performed using Welch’s t test. Error bars are SEM. (D) Schematic for specifying Cx3cr1CreERT2 × Casp1FL/FL genetic manipulation to microglia during T. gondii infection. (E) Number of parasite genomes present in peritoneal exudate cells at 8 days post-infection. (F) Number of CD4+ and CD8+ T cells producing IFN-γ in the spleen at 8 days post-infection. (G) Number of parasite genomes present in the brain at 6 weeks post-infection. Error bars are SEM (H) Number of monocytes, iNOS+ monocytes, and CD4+ and CD8+ T cells. (I) Frequency of monocytes in the brain as a percentage of live cells. (E and F) One experimental replicate containing WT/WT, FL/FL, and FL/FL + Repop; second replicate containing FL/FL and FL/FL + Repop, both utilizing male mice. Statistics involving WT/WT were performed using Welch’s t test. Error bars are SEM. (G) Four experimental replicates in males. (H and I) Five experimental replicates performed: four experiments in male mice, one experiment in female mice. Statistics were performed using randomized block ANOVA with post hoc Tukey’s test. All data points are represented in graphs. Error bars are SEM. DISCUSSION Cx3cr1CreERT2 remains one of the most popular tools to target microglia; it also induces recombination in peripheral immune cells. Initially thought to be microglia specific, subsequent studies revealed robust targeting of CNS BAMs, prompting the development of more selective Cre lines.14,15,46 These efforts have led to the development of mice with Cre driven by the P2ry12, HexB, and Tmem119 promoters.47-49 While these newer tools do not target BAMs, they fail to recombine all microglia, targeting only ~50% of microglia.16,17 In contrast, 4 weeks posttamoxifen treatment, Cx3cr1CreERT2 targets >95% of microglia but also, depending on the tissue, targets ~20%–80% of peripheral macrophages. Thus, while highly effective for targeting microglia, Cx3cr1CreERT2 requires careful validation when used to infer microglia-specific functions. The slow turnover of some targeted peripheral Cx3cr1CreERT2 macrophages may be a confounding factor to studying microglia in systems with strong peripheral immune components, such as lipopolysaccharide (LPS) stimulation, experimental autoimmune encephalomyelitis (EAE), or CNS infections like T. gondii. Prior studies have demonstrated that PLX5622 effectively depletes peripheral macrophages, prompting us to investigate whether it also targets long-lived Cx3cr1CreERT2-targeted macrophages. Across all tissues analyzed, PLX5622 treatment led to ~60%–98% depletion of Cx3cr1CreERT2-targeted macrophages (ZsGreen expressing). However, after allowing for repopulation, only ~30%–70% of ZsGreen-positive peripheral macrophages were replaced by a ZsGreen-negative progenitor, suggesting that residual ZsGreen-positive cells contribute to niche re-occupation. Since CSF1R signaling is required for monocyte differentiation into macrophages, neither resident nor infiltrating monocytes can occupy the tissue compartment during active CSF1R antagonist treatment. Upon drug withdrawal, both surviving resident macrophages and newly recruited monocyte-derived cells may repopulate the tissue niche. This competition is apparent when comparing the extent of ZsGreen-positive macrophage depletion versus their replacement. For example, in tissues such as the meninges and lungs—both of which contain self-renewing resident macrophages—we observed ~98% depletion but only ~50% replacement of ZsGreen-positive macrophages, consistent with a contribution from surviving resident cells. By contrast, the small intestine mucosa, where macrophages are monocyte derived, showed ~45% depletion and ~35% replacement, suggesting limited input from resident macrophages.2,8,15,36,50 At steady state, monocyte engraftment into tissue macrophage niches reaches its asymptote at approximately 12 weeks of age; therefore, mouse age may influence the competition between resident and bone marrow-derived macrophages during repopulation. While performing additional rounds of depletion and repopulation may enhance replacement efficiency in peripheral compartments, prior studies have shown that repeated CSF1R inhibition can compromise microglial self-renewal and promote unintended replacement by peripheral cells.51,52 Overall, the transient inhibition of CSF1R using PLX5622 described here aligns with prior studies examining the self-renewal potential and monocyte replacement of tissue-resident macrophages across diverse tissues. Recent advances have reshaped the field’s understanding of macrophage dynamics. It is now clear that macrophage subsets differ in lifespan, origin, and renewal capacity. However, the mechanisms supporting persistence—beyond CSF1R signaling—remain unclear. In this study, we demonstrated that MHCII-positive skin macrophages, which others have shown to have bone marrow origins, do not persist to 4 months, but MHCII-negative skin macrophages of embryonic origin do persist.22 This would suggest that ontogeny dictates the turnover of these macrophages. On the contrary, in the meninges, our data and others show that both MHCII-positive (bone-marrow) and MHCII-negative (embryonic)-derived macrophages have slow turnover, suggesting that tissue cues may override ontogeny.15 Identifying the signals that allow for macrophage persistence, independent of CSF1R, is of great importance. Inflammation can induce the initial loss and replacement of tissue macrophages, and it is unclear whether macrophage depletion and repopulation affect subsequent immune responses.11 For example, yolk sac-derived large peritoneal macrophages “disappear” following numerous stimuli and are replaced by bone marrow-derived macrophages.11,53,54 Similar loss of primordial macrophages have been observed in the lung, raising the question of whether immune reactions to pathogens would be affected by the ontogeny of macrophages present in a tissue.55 During lymphocytic choriomeningitis virus (LCMV) infection, this appears to be the case, as the ontogeny of meningeal macrophages affects viral control. Mice with postnatally derived MHCII-positive meningeal macrophages have decreased viral load in the meninges and CNS compared to meninges composed of MHCII-negative embryonic macrophages. These findings suggest that MHCII-positive postnatal meningeal macrophages are superior to embryonic MHCII-negative macrophages at controlling LCMV.37 On the other hand, during T. gondii infection, shifting meningeal and peritoneal macrophages toward being MHCII positive did not affect immune priming or control of T. gondii. These disparate results might be due in part to LCMV directly infecting the meninges while T. gondii resides largely within parenchymal neurons. These data suggest that during T. gondii infection, embryonic and monocyte-derived macrophages are sufficient for immune response generation and parasite control. However, due to the chronic nature of T. gondii infection, we were unable to test the impact of monocyte-derived macrophages on the resolution of inflammation. We have previously shown that caspase-1 promotes control of peripheral T. gondii infection, and here we show that mice harbor more parasites in their brain during chronic infection when they lack caspase-1.19 The latter finding is consistent with previous work, which demonstrated that CNS-resident macrophages release IL-1α through gasdermin D pores to promote monocyte recruitment into the CNS.18 Given these studies, we hypothesized that microglial caspase-1 would promote parasite control in the CNS through the recruitment of monocytes. Utilizing Cx3cr1CreERT2 × Casp1FL/FL mice, we observed impaired parasite control in the CNS, which was associated with an inability to recruit monocytes into the CNS in Cx3cr1CreERT2 × Casp1FL/FL mice. However, we also observed that Cx3cr1CreERT2 × Casp1FL/FL mice had impaired control of the acute stage of infection in the peritoneum. Notably, when Casp1 deletion was confined to microglia using transient CSF1R inhibition, both peripheral and CNS defects in parasite control were restored, demonstrating that microglial caspase-1 is not required for CNS control of T. gondii. These findings underscore that increasing the specificity of recombination to microglia within the Cx3cr1CreERT2 framework can yield results that diverge substantially from those obtained using broader myeloid-targeting strategies. Furthermore, these data suggest that a long-lived, non-microglial Cx3cr1+ macrophage population mediates caspase-1-dependent control of infection. Importantly, transient CSF1R inhibition in conjugation with Cx3cr1CreERT2 provides a method to disentangle microglial versus long-lived peripheral macrophage function utilizing one mouse line. It also highlights the long-lived nature of Cx3cr1CreERT2-targeted myeloid cells, the robustness of PLX5622 depletion of peripheral macrophages, the repopulation dynamics of peripheral macrophages, and the impact of macrophage depletion and repopulation on peripheral and CNS T. gondii infection. Limitations of the study In this study, we found that PLX5622 treatment decreased the presence of labeled tissue macrophages in peripheral tissues. The presence of this ZsGreen-negative population suggests macrophage replacement from the bone marrow by progenitor cells, but we did not label bone marrow-derived cells or monocytes, which would allow us to make a more definitive conclusion on the origin of the cells that replace labeled macrophages in this system. STAR★METHODS EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS WT (C57BL/6J), Cx3cr1CreERT2/CreERT2 (#020940)13 and ROSA26 Ai6/Ai6 (007906) strains were obtained from The Jackson Laboratory and maintained within our animal facility. Casp1FL/FL mice were provided by R. Flavell5.56 Cx3Cr1CreERT2/CreERT2 mice were crossed with Casp1FL/FL mice to generate Cx3Cr1CreERT2/+ × Casp1FL/FL mice. The type II T. gondii strain Me49 was maintained in Swiss Webster mice (#024, Charles River Laboratories) and passaged through CBA/J mice (Jackson Laboratory). For experiments, tissue cysts were collected from chronically infected (>3 weeks) CBA/J mice (#000656, The Jackson Laboratory). 7–10-week-old age and sex-matched mice were infected by intraperitoneal (i.p.) injection of 10 cysts of Me49 in 200 μL of 1X PBS. PLX5622 was purchased from Chemgood and formulated in AIN-76A Rodent Diet at 1,200 ppm by Research Diets Inc. Control diet was AIN-76A Rodent Diet. To induce recombination, five i.p. injections of tamoxifen in corn oil (4 mg per 20 g body weight, Sigma-Aldrich) were administered i.p between 4 and 6 weeks of age. PLX5622 was administered at 5–7 weeks of age and repopulation occurred between 6.5 and 10.5 weeks of age. All procedures involving animal care and use were approved by and conducted in accordance with the University of Virginia’s Institutional Animal Care and Use Committee (IACUC) under protocol number 3968. METHOD DETAILS Tissue processing Immediately after sacrifice the superior vena cava was punctured and 10 μL of blood was collected and placed in PBS containing 0.025 M EDTA. Blood samples were spun down and treated with 2x RBC lysis solution (0.16 M NH4Cl) before resuspending in FACS buffer (1X PBS, 0.2% BSA, and 2 mM EDTA). Immediately after blood collection, transcardiac perfusion with 20 mL cold 1X PBS was performed. The brain was sliced along the midline. Half the brain was placed in 4% paraformaldehyde (PFA) for immunohistochemistry (IHC) and the other half was passaged through an 18g needle in 3 mL HBSS. DNase (1mg/mL, Roche, ref. 10104159001) and papain (4U/mL, Worthington Biochemical, Ref LS003126) were added for 45 min at 37°C. The brain homogenate was then passed through a 70 μM filter (Corning, ref. 352350), and spun down at 1,500 rpm for 10 min. Next, the resulting pellet was resuspended in 40% Percoll (Cytiva, ref. 17089109) and spun at 650 x g for 25 min. The mononuclear cell pellet was resuspended in cRPMI (cRPMI; 10% FBS [Gibco], 1% penicillin/streptomycin [Gibco], 1% sodium pyruvate [Gibco], 1% non-essential amino acids [Gibco], and 0.1% 2-Mercaptoethanol [Life Technologies]). The middle lobe of the lung was minced using dissection scissors in a 48 well plate. The lung homogenate was then digested with DNase (1mg/mL, Roche, ref. 10104159001), collagenase/dispase (25μg/mL, Sigma-Aldrich, ref. 10369638001), and papain (4 U/mL, Worthington Biochemical, Ref LS003126) for 1 h at 37°C. The sample was triturated with a p1000 pipette tip and then passed through a 40 μM filter (Corning, ref. 352340). Cells were spun down and resuspended in FACS buffer. For collecting skin macrophages, dorsal and ventral tissue from the ear was placed in a 48 well plate and minced with dissection scissors. The tissue was then incubated with DNase (1mg/mL) and Liberase (0.25mg/mL, Sigma-Aldrich, ref. 5401119001) for 2 h at 37°C then trypsin (Gibco, ref. 15400-054) was added to a final concentration of 0.25% and the sample was further incubated for 10 min at 37°C. Cells were then triturated with a p1000 pipette tip and then passed through a 40 μM filter (Corning, ref. 352340). The cells were spun down at 1,500 rpm for 5 min, triturated with a p200 pipette tip, and spun at 1,500 rpm for 5 min before resuspending in FACS buffer. For macrophages from the spleen and DCLN, tissue was placed in a 24 well plate containing 200 μL cRPMI and homogenized using a 1 mL syringe plunger. Intact DCLN were also placed in 4% PFA for IHC. Once all tissues were collected DNase (1mg/mL) and 1x Collagenase/dispase (25μg/mL) were added to lymphatic samples and incubated in cRPMI for 20 min at 37°C. Samples were then titrated with a p1000 pipette tip and passed through 40 μM filter. The DCLNs were resuspended in FACS buffer. The spleens were further processed with RBC lysis buffer (0.16 M NH4Cl) for 2 min then spun down at 1,500 rpm for 5 min. The mononuclear cell pellet was resuspended in FACS buffer. Peritoneal exudate cells were isolated via peritoneal lavage with 3 mL PBS, spun down, and resuspended in FACS buffer. To isolate meningeal macrophages, dural meninges were split in half along the sagittal suture, half of meninges were used for IHC, while the other half were used for immune cell isolation and flow cytometry. Meningeal macrophages were further isolated by placing meninges in 500 mL cRPMI containing Collagenase VIII (1mg/mL, Sigma-Aldrich, ref. 11088866001) and Collagenase D (1mg/mL, Sigma-Aldrich C2139) for 30 min at 37°C. The meningeal tissue was then triturated with a p1000 pipette tip and passed through 70 μM filter (Corning, ref. 352340). Mono-nuclear meningeal cells were then spun down and resuspended in FACS. For visualization of macrophages within the small intestine, a two cm piece of jejunum was isolated and cleaned by passing 10mL PBS through the intestinal lumen using a 10 mL syringe. The intestinal section was then placed in 4% PFA. For intracellular cytokine staining, mononuclear cells were resuspended in 50 μL cRPMI with Brefeldin A (10μg/mL, Selleckchem Cat#S7046) or Brefeldin A plus PMA (100ng/mL)/ionomycin (0.5μg/mL) (Sigma-Aldrich Cat#P1585, Cat#I0634) for 5 h at 37°C before staining. For CD11b cell enrichment, CD11b microbeads (Miltenyi Biotec Cat#130-093-634) were used per manufacturer’s instructions along with LS Columns (Miltenyi Biotec Cat#130-042-401). Flow cytometry Single cell suspensions were resuspended in Fc Block, made in FACS buffer (1x PBS, 0.2% BSA, and 2 mM EDTA) with 0.1 μg/mL 2.4G2 Ab (BioXCell, Cat#CUS-HB-197) and 0.1% rat gamma globulin (Jackson Immunoresearch, Cat#012-000-002) for 10 min. For experiments involving T. gondii immune response or naive immune state, fixable live/dead efluor780 (Invitrogen Ref, 65–0865014) was used at 1:800; for experiments tracking ZsGreen-expressing cells, fixable viability stain 620 (BD Horizions, ref. 564996) was used at 1:100. Surface stains used at 1:200 included: CD45 AF700 (Biolegend, ref. 103128), CD11b PerCP-Cyanine5.5 (Invitrogen, ref. 45–0112082), Ly6g BV711 (Biolegend,ref. 127643), CD3 PE-Cy7 (Invitrogen, ref. 25-0031-81), CD4 BV650 (BD Horizon, ref. 563232), CD8 BV421 (BD Horizon, ref. 5098056), CD11c eFluor 506 (Invitrogen, ref. 69-0114-82), CD44 PE-efluor 610 (Invitrogen, ref. 61-0441-82), CD62L Novafluor Blue 660-40s (Invitrogen, Ref M006T02B07-N), CD115 APC (Biolegend, ref. 135510), CD64 PE/Cy7 (Biolegend, ref. 139314), F4/80 APC/Cy7 (Biolegend, ref. 157315), CD3 PE-CF594 (BD Horizon, ref. 562332) Lyve-1 eFluor 660 (Invitrogen, ref. 50-0443-83), MHCII SB780 (Thermo Scientific, ref. 78-5321-82), Ly6C PE-Cy7 (Invitrogen, ref. 25-5932-82), NK1.1 BV711 (Biolegend, ref. 108745), CD44 APC-eFluor 780 (Invitrogen, ref. 47-0441-82), Cx3cr1 Pacific Blue (Biolegend, ref. 149038). Ly6c PE (Invitrogen, ref. 12-5932-82) was used at 1:400. Cells were stained for 30 min on ice then fixed in 1X BD Pharmingen Fix/Perm (ref. 51–9011319) diluted in Fixation/Perm Diluent (Invitrogen, ref. 00-5223-56) for 30 min on ice. Cells were then washed and resuspended in 1X permeabilization buffer (Invitrogen, ref. 00-8333-56). Intracellular stains were all used at 1:200 in 1X permeabilization buffer for 30 min on ice. Antibodies included FoxP3 eFluor 450 (Invitrogen, ref. 48-5773-82), iNOS APC (Invitrogen, ref. 17-5920-82), T-bet PE-Cy7 (Invitrogen, ref. 25-5825-82), IL-17 PE (BD Pharmingen, ref. 561020), IFN-γ APC (Invitrogen, ref. 17-7311-81), TNFα PE (Invitrogen, ref. 12-7321-81). All flow cytometry experiments were performed on a Cytek Aurora spectral flow cytometer with either a 3 laser or 5 laser configuration. Flow cytometry data was analyzed using FlowJo_V10.9.0. Microscopy and image analysis Tissues collected for confocal microscopy were first fixed in 4% PFA for 24 h at 4°C. The tissues were then placed in 30% sucrose for 24 h at 4°C, embedded in OCT (Tissue Tek), and frozen on dry ice. The samples were then stored at −20°C before being cut into 40 μm sections using a CM1950 cryostat (Leica). Sections were placed either directly onto Superfrost microscope slides (Fisherbrand) or into a 24-well plate containing PBS. Sections were then blocked in 1X PBS containing 2% donkey serum (Jackson ImmunoResearch), 0.1% Triton, 0.05% Tween 20, and 1% BSA for 1 h at room temp. Samples were then incubated with primary antibody IBA1 (FujiFilm Biosciences, ref. 019–19741, 1:200) diluted in blocking buffer at 4°C overnight. The stained sections were then washed three times with 1X PBS containing 0.05% Tween 20 and then incubated with secondary antibody donkey anti-rabbit AF594 at 1:200 in blocking buffer (Jackson Immunoresearch, ref. 711-585-152) for 2 h at room temp. Sections were then washed three times with 1X PBS containing 0.05% Tween 20 and then incubated with DAPI (Thermo Scientific) for 5 min before mounting with aquamount (Lerner Laboratories) and cover slipped (Fisherbrand). z stack images were acquired using Leica SP8 scanning confocal. Images were analyzed with either ImageJ or Imaris version 10.1.1. RT-qPCR RNA was isolated from brain by chloroform/isopropanol extraction. Then cDNA was generated using a High-Capacity Reverse Transcription Kit (Applied Biosystems). Quantitative PCR was performed using 2X Taq Master Mix (Bioline) and Taq Man gene expression assays (Applied Biosystems) on a CFX384 Real-Time System thermocycler (Bio-Rad Laboratories). Genes were normalized to murine Hprt and the 2 (−ΔΔCT) method was utilized to obtain relative expression.57 IDT gene probe for Casp1 (Mm.PT.58.8975671.gs) was used. The following ThermoFisher mouse gene probes were used: Hprt (Mm00446968_m1), Ifit3 (Mm01704846_s1), Ifit1 (Mm00515153_m1), Oasl2 (Mm01201449_m1), Irf7 (Mm00516793_g1), Siglec1 (Mm00488332_m1), Hba-a2 (Mm02580841_g1). T. gondii qPCR DNA from brain homogenate or peritoneal exudate cells was isolated using the Isolate II Genomic DNA Kit (Bioline, BIO-52067). Brains were first homogenized in 1X PBS using the Omni TH tissue homogenizer (Omni International) before DNA was isolated with the genomic DNA kit. To detect T. gondii parasite genomes 500 ng or 1 μg DNA was loaded into a 384 well qPCR plate (VWR, Cat#82006-678) containing SensiFAST Probe No-ROX (Bioline, BIO-86005) and primers that detect a T. gondii 529 bp repeat region which was amplified using a CFX384 Real-Time System (Bio-Rad)5.58 T. gondii isolated from human foreskin fibroblasts was used to make a serial standard curve from 30 to 300,000 genome copies to determine the number of T. gondii genomes per μg of tissue DNA. ELISA Serum cytokine levels were detected according to R&D systems instructions using DuoSet ELISA kits (IFN-γ, Cat# DY485-05) with the DuoSet Ancillary Reagent Kit 2 (Cat# DY008B) or Quantikine ELISA (IL-12, Cat#M1240). Analysis of bulk RNA sequencing Mapped read counts for the GEO: GSE245107 dataset were obtained from the NCBI Gene Expression Omnibus (GEO). Utilizing R studio (2025.05.1) to run R (version 4.4.0), genes with fewer than 1 count across all samples were filtered out. Normalization was performed using the Trimmed Mean of M-values (TMM) method from the edgeR package, and log2 counts per million (CPM) were calculated. Differential expression analysis was conducted using the DESeq2 and edgeR Bioconductor packages. Visualization of normalized expression and differential expression results were generated using ggplot2 and vplot. The top 50 differentially expressed genes, ranked by adjusted p-value, were subjected to gene ontology enrichment analysis for biological processes using the en-richGO function from the cluster Profiler package. QUANTIFICATION AND STATISTICAL ANALYSIS Data was graphed in GraphPad Prism 9 or in R. Variability between experimental dates was accounted for using a randomized block ANOVA in R using lme4 and emmeans packages. This analysis models experimental groups as a fixed effect and experimental day as a random effect.59 Outliers were removed using ROUTs method with a Q value of 16.60 All p values are indicated in figures. Supplementary Material Supplemental information can be found online at https://doi.org/10.1016/j.celrep.2026.117411. KEY RESOURCES TABLEREAGENT or RESOURCESOURCEIDENTIFIERAntibodies2.4G2BioXCellCat#CUS-HB-197CD45 AF700BiolegendCat#103128; RRID:AB_493715CD11b PerCP-Cyanine5.5InvitrogenCat#45–0112082; RRID:AB_953558Ly6g BV711BiolegendCat#127643; RRID:AB_2565971CD3 PE-Cy7InvitrogenCat#25-0031-81; RRID:AB_469571CD4 BV650BD HorizonCat#563232; RRID:AB_2738083CD8 BV421BD HorizonCat#5098056CD11c eFluor 506InvitrogenCat#69-0114-82; RRID:AB_2637427CD44 PE-efluor 610InvitrogenCat#61-0441-82; RRID:AB_2574554CD62L Novafluor Blue 660-40sInvitrogenCat#M006T02B07-NCD115 APCBiolegendCat#135510; RRID:AB_2085221CD64 PE/Cy7BiolegendCat#139314; RRID:AB_2563904F4/80 APC/Cy7BiolegendCat#157315; RRID:AB_2894638CD3 PE-CF594BD HorizonCat#562332; RRID:AB_11154041Lyve-1 eFluor 660InvitrogenCat#50-0443-83MHCII SB780Thermo ScientificCat#78-5321-82; RRID:AB_2744917Ly6C PE-Cy7InvitrogenCat#25-5932-82; RRID:AB_2573503NK1.1 BV711BiolegendCat#108745; RRID:AB_2563286CD44 APC-eFluor 780InvitrogenCat#47-0441-82; RRID:AB_1272244Cx3cr1 Pacific BlueBiolegendCat#149038; RRID:AB_2632858Ly6c PEInvitrogenCat#12-5932-82; RRID:AB_10804510FoxP3 eFluor 450InvitrogenCat#48-5773-82; RRID:AB_1518812iNOS APCInvitrogenCat#17-5920-82; RRID:AB_2573244T-bet PE-Cy7InvitrogenCat#25-5825-82; RRID:AB_11042699IL-17 PEBD PharmingenCat#561020; RRID:AB_10584331IFN-γ APCInvitrogenCat#17-7311-81; RRID:AB_469503TNFα PEInvitrogenCat#12-7321-81; RRID:AB_466198IBA1FujiFilm BiosciencesCat#019–19741; RRID:AB_839504Donkey anti-rabbit AF594Jackson ImmunoresearchCat#711-585-152; RRID:AB_2340621Rat gamma globulinJackson ImmunoresearchCat#012-000-002Chemicals, peptides, and recombinant proteinsPLX5622ChemgoodCat#C-1521TamoxifenSigma-AldrichCat#T5648DNaseRocheCat#10104159001PapainWorthington BiochemicalCat# LS003126PercollCytivaCat#17089109Collagenase/dispaseSigma-AldrichCat#10369638001LiberaseSigma-AldrichCat#5401119001TrypsinGibcoCat#15400-054Collagenase VIIISigma-AldrichCat#11088866001Collagenase DSigma-AldrichCat#C2139Brefeldin ASelleckchemCat#S7046PMASigma-AldrichCat#P1585IonomycinSigma-AldrichCat#I0634Critical commercial assaysCD11b MicroBeadsMiltenyi BiotecCat#130-093-634DuoSet IFN-γ ELISA kitR&D SystemsCat#DY485-05DuoSet Ancillary Reagent Kit 2R&D SystemsCat#DY008BQuantikine IL-12 ELISAR&D SystemsCat#M1240Deposited dataFu et al. Bulk SequencingGEOGEO: GSE245107Babcock et al.Figshare https://doi.org/10.6084/m9.figshare.32086281 Experimental models: Organisms/strainsC57BL/6JJackson LaboratoryCat#000664; RRID:IMSR_JAX:000664 Cx3cr1 CreERT2/CreERT2 Jackson LaboratoryCat#020940; RRID:IMSR_JAX:020940ROSA26 Ai6/Ai6Jackson LaboratoryCat#007906; RRID:IMSR_JAX:007906 Casp1 FL/FL Case et al.,56 PNASN/ASwiss Webster miceCharles River LaboratoriesCat#024CBA/JJackson LaboratoryCat#000656; RRID:IMSR_JAX:000656OligonucleotidesHprtThermoFisherCat#Mm00446968_m1Ifit3ThermoFisherCat#Mm01704846_s1Ifit1ThermoFisherCat#Mm00515153_m1Oasl2ThermoFisherCat#Mm01201449_m1Irf7ThermoFisherCat#Mm00516793_g1Siglec1ThermoFisherCat#Mm00488332_m1Hba-a2ThermoFisherCat#Mm02580841_g1Casp1IDTCat#Mm.PT.58.8975671.gsSoftware and algorithmsFlowJo V10FlowjosoftwareRRID: SCR_008520ImageJNIHRRID: SCR_003070R (version 4.4.0)r-projectRRID:SCR_001905Rstudio (2025.05.1)PositRRID:SCR_000432Imaris (10.1.1)OxfordN/AGraphpad prism 9GraphPadRRID:SCR_002798BioconductorBioconductorRRID:SCR_006442 KEY RESOURCES TABLE Highlights Cx3cr1-expressing cells require caspase-1 to limit Toxoplasma gondii infection Cx3cr1-expressing cells require caspase-1 to limit Toxoplasma gondii infection Cx3cr1CreERT2 targets long-lived peripheral macrophages depletable by PLX5622 Cx3cr1CreERT2 targets long-lived peripheral macrophages depletable by PLX5622 PLX5622 depletion and recovery restricts Cx3cr1CreERT2 targeting to microglia PLX5622 depletion and recovery restricts Cx3cr1CreERT2 targeting to microglia Caspase-1 in Cx3cr1+ cells, but not microglia, controls T. gondii Caspase-1 in Cx3cr1+ cells, but not microglia, controls T. gondii ACKNOWLEDGMENTS This work was funded by National Institutes of Health grants R01NS112516 and R01NS134747 to T.H.H., T32AI007496 to I.W.B. and A.E.M., 5T32GM136615 to L.A.S., 5T32AI007046 to A.G.K., and 5T32NS1156573 to S.A.L.; the University of Virginia Wagner Fellowship to S.A.L.; the Harrison Undergraduate Award to A.E.S.; the Double Hoo Research Grant to S.A.; and a Shannon Midcareer Fellowship to T.H.H. We would like to thank Stephanie Moy for assistance in creating the graphical abstract. Schematics were created using Biorender. Footnotes RESOURCE AVAILABILITY Lead contact Requests for further information and resources should be directed to and will be fulfilled by the lead contact, Tajie H. Harris (tajieharris@virginia.edu). Materials availability This study did not generate unique reagents. Data and code availability This paper did not generate original code. All data underlying the findings reported in this manuscript are deposited in Figshare: https://doi.org/10.6084/m9.figshare.32086281. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request. DECLARATION OF INTERESTS The authors declare no competing interests. REFERENCES Associated Data Supplementary Materials